Syngene International expands ongoing collaboration with Bristol-Myers Squibb

To set up new facility, expansion of team and extend agreement upto 2026

Syngene International announced that it has expanded its ongoing collaboration with Bristol-Myers Squibb. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities.

As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively in support of Bristol-Myers Squibb.

 

Powered by Capital Market - Live News